CRSP Crispr Therapeutics AG
Company Analysis
Latest News
CRISPR Therapeutics reports promising interim CTX112 results in autoimmune trial
CRISPR Therapeutics today announced interim results from its ongoing Phase 1/2 clinical trial of CTX112, an allogeneic CAR-T cell therapy for systemic lupus...
🔴 Crispr Therapeutics falls 4.1% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🟢 Crispr Therapeutics rises 4.3% — Biotech Sector Rallies on Positive Clinical Data and Regulatory News
With Biotech (XBI) up 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Crispr Therapeutics rises 5.3% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Crispr Therapeutics is trading 4.32% down today amid biotech-sector weakness
Crispr Therapeutics is trading at $50.09, down 4.32%, amid biotech-sector weakness. - XBI is down 2.04% during the session, while the Nasdaq Composite is down...
🔴 Crispr Therapeutics is trading 4.45% down on October 6, 2026 as biotech shares weaken
Crispr Therapeutics is trading at $54.79, down 4.45%, amid broader biotech weakness. - No clear company-specific catalyst for the decline was identified. -...
🟢 Crispr Therapeutics is trading 4.4% up — catalyst remains unclear
Crispr Therapeutics is trading 4.41% higher at $59.87, with no clear company-specific catalyst identified for the October 6 move. - The latest listed company...
🟢 Crispr Therapeutics is trading 5.7% up in pre-market with no identified company-specific catalyst
Crispr Therapeutics is trading 5.7% higher in pre-market at $60.59, versus the October 5 close of $57.34; no October 6 company announcement explaining the move...
🟢 Crispr Therapeutics is trading 4.3% up
Crispr Therapeutics is trading at $56.42, up 4.32%, with no clear company-specific catalyst identified for the September 29 move. - A September 29 article...
Anthropic Discovers CRISPR-Like Gene Tool, Sending Biotech Stocks Lower
Anthropic’s Claude AI discovered a previously unknown enzyme system in bacterial DNA called array-associated reverse transcriptase (ART). The system resembles...
🔴 Crispr Therapeutics is trading 4% down today as oil prices and Treasury yields rise
Crispr Therapeutics is trading 4.01% lower at $56.66 as U.S. equities weaken amid higher oil prices, rising Treasury yields, and softer risk appetite on...
🟢 Crispr Therapeutics rises 4.0% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 Crispr Therapeutics is trading 4.07% up today as risk appetite strengthens
Crispr Therapeutics is trading 4.07% up now at $58.86 as risk appetite strengthens across U.S. equities. - The S&P 500 is up 1.02% and the Nasdaq Composite is...
🟢 Crispr Therapeutics is trading 12% up today as markets rebound after the Federal Reserve decision
Crispr Therapeutics is trading 11.99% up now at $58.47 as U.S. markets recover after the Federal Reserve’s September 16 policy decision. - Stronger risk...
🟢 Crispr Therapeutics is trading 4.3% up today as U.S. markets rebound after Fed decision
Crispr Therapeutics is trading 4.3% up at $54.43 as U.S. markets rebound following the Federal Reserve’s September 16 policy decision. - The Nasdaq is up...
🟢 Crispr Therapeutics is trading 4.02% up today ahead of scheduled Morgan Stanley presentation
Crispr Therapeutics is trading 4.02% up at $53.80, possibly supported by investor interest ahead of its scheduled Morgan Stanley presentation. - The stock is...
🔴 Crispr Therapeutics is trading 4.3% down today amid biotech pressure following Novartis trial failure
Crispr Therapeutics is trading 4.3% down at $53.37 after opening-market weakness on September 8, 2026, amid biotechnology-sector pressure following Novartis’s...
CRISPR Therapeutics Presents Positive One-Year Data for CTX310
CRISPR Therapeutics presented positive durability data from its Phase 1a trial for CTX310. The company presented this data at the European Society of...
🔴 Crispr Therapeutics is trading 4.3% down today with no clear company-specific catalyst
Crispr Therapeutics is trading 4.3% down at $58.30, with no clear company-specific catalyst identified for the August 26, 2026 decline. - Its latest major...
🟢 Crispr Therapeutics rises 4.2% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...